Simris Group appoints Tiffany J Vora as Strategic Advisor
pharmafile | July 28, 2026 | Appointment | | Simris Group
Simris Group has appointed Tiffany J Vora as a Strategic Advisor. This follows the recent appointment of Andreas Pahl as CEO of Simris Biologics, a subsidiary focused on unlocking the next generation of effective, naturally derived, novel payloads for antibody-drug conjugates (ADCs). In her role as Strategic Advisor to the Group, Vora will support engagement with the broader US biotechnology, financing and innovation ecosystem, while providing advice and support to Pahl and the Simris Biologics team.
Vora is a biotechnology scientist, entrepreneur, educator, and advisor with experience across molecular biology, genomics, biotechnology innovation, and drug discovery. Through her work with technology companies, startups, scientific organisations and the broader innovation ecosystem, she has developed an extensive network across the US biotechnology sector.
Daniel Kubitza, interim CEO of Simris Group, said: “Tiffany brings deep scientific expertise and an extensive network across the US biotechnology ecosystem. Her insights will be invaluable as Simris Group strengthens its industry and investor engagement.”
Vora added: “Simris Group has built a strong scientific foundation and a differentiated approach to ADC payload discovery based on nature-derived technologies. I look forward to working with Andreas and the team to advance its innovative ADC platform, helping create value for both patients and shareholders.”
Vora is currently a Singularity Fellow in Biotechnology and a contributor to EY Executive Learning programmes. She also serves as a Non-resident Senior Fellow at the Atlantic Council’s GeoTech Center and holds leadership and advisory roles with organisations including Humanity in Deep Space and Explore Mars. Earlier in her career, she worked in drug target validation at Bristol-Myers Squibb before founding and advising several science and innovation-focused ventures.
